Navigation Links
Exiqon Diagnostics Partners With MedTrust Online to Promote KRAS Mutation Analysis and Other Innovative Molecular Oncology Diagnostic Services to Oncologists
Date:5/29/2009

for cancer patients. The aim is to optimize the use of existing medicine and avoid unnecessary and non-effective treatment. By using molecular diagnostic tests that analyze the genetic profile of each patient's tumor, treatment selection can be optimized for individuals. Exiqon is uniquely positioned to develop such new diagnostic tests. Exiqon already markets diagnostic tests that based on fresh tumor tissue enable doctors to test whether their patients are resistant to one or more of the chemotherapies offered to treat these patients and help them select an efficacious treatment.

Exiqon's new molecular diagnostic products are based on the LNA(TM) technology that enables testing on fixed tissue. Launch of the first molecular diagnostic product was announced in December 2008. A number of new products will follow in the years ahead. Using the LNA(TM) technology is what has allowed Exiqon to establish a position for itself as one of the market's leading providers of research products for gene expression analysis. These research products are used by university scientists and in the pharmaceutical industry around the world to make groundbreaking discoveries about the correlation between gene activity and the development various diseases.

Exiqon is also collaborating with pharmaceutical companies in their effort to develop new medicines based on biomarkers (Personalized Medicine). Exiqon has more than 200 employees and is listed on the NASDAQ OMX in Copenhagen and categorized as a biotech company (Small Cap+). Exiqon is financed until expected breakeven in 2011.

For further information, please visit www.exiqon.com.


'/>"/>
SOURCE MedTrust Online
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Norgen Biotek Corp. Announces OEM Manufacturing & Supply Agreement with Exiqon A/S
2. Exiqon Announces Positive Clinical Data From EORTC Clinical Trial Showing Oncotech EDR Assay Predicts Resistance to Platinum-Based Therapy in Ovarian Cancer
3. Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc.
4. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
5. Report Regarding the Managements and Closely Related Parties Transactions With Securities in Exiqon A/S
6. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
7. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
8. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
9. Exiqon: Major Shareholder Announcement
10. Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting
11. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Small addition to cancer drug may make big difference 2Small addition to cancer drug may make big difference 3U. of I. business instructional facility achieves top 'green' standard 2U. of I. business instructional facility achieves top 'green' standard 3Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 3Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 4Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 5Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 6Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 7Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 8Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 9Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 10Tennis Elbow Shin Splints and Carpal Tunnel Syndrome Could Be a Thing of the Past Due to New Efforts with Sports Musculoskeletal Ultrasound 51869 1Tennis Elbow Shin Splints and Carpal Tunnel Syndrome Could Be a Thing of the Past Due to New Efforts with Sports Musculoskeletal Ultrasound 51869 2Tennis Elbow Shin Splints and Carpal Tunnel Syndrome Could Be a Thing of the Past Due to New Efforts with Sports Musculoskeletal Ultrasound 51869 3Tennis Elbow Shin Splints and Carpal Tunnel Syndrome Could Be a Thing of the Past Due to New Efforts with Sports Musculoskeletal Ultrasound 51869 4Fitness Gurus Warn Women Not To Give Up On Their Diet Just Because Summer Has Arrived 51866 1Fitness Gurus Warn Women Not To Give Up On Their Diet Just Because Summer Has Arrived 51866 2Mayo Clinic 26apos 3Bs Dr Denis Cortese Receives NCHL 26apos 3BS 2009 National Healthcare Leadership Award 51863 1Mayo Clinic 26apos 3Bs Dr Denis Cortese Receives NCHL 26apos 3BS 2009 National Healthcare Leadership Award 51863 2Mayo Clinic 26apos 3Bs Dr Denis Cortese Receives NCHL 26apos 3BS 2009 National Healthcare Leadership Award 51863 3Mayo Clinic 26apos 3Bs Dr Denis Cortese Receives NCHL 26apos 3BS 2009 National Healthcare Leadership Award 51863 4